期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

螺旋内脂与缬沙坦治疗慢性心力衰竭的对照研究 被引量：2

下载PDF
导出
摘要 目的 观察在常规抗心衰药物治疗的基础上联合螺旋内脂治疗慢性心衰与联合缬沙坦治疗CHF疗效的比较,旨在了解不同药物联合应用的疗效.方法 选择我院2003年1月～2005年10月70例CHF患者,男38例,女32例,年龄50～74岁,(63±11.5)岁,心功能Ⅱ～Ⅲ级,EF＜45%,其中心功能Ⅱ级30例,心功能Ⅲ级40例, 随机分为螺旋内脂治疗组36例和缬沙坦对照组34例.两组年龄、性别、心功能及病因构成差异均无统计学意义(P＞0.05).治疗组螺旋内脂40mg·次-1·d-1,病情稳定后逐步调整到20mg,1次/d.对照组缬沙坦40mg·次-1·d-1,1周后加到靶剂量80mg 1次/d.规范用药6个月.结果 两组治疗改善NYHA,分别为91.7%与94.1%,两组对比差异无统计学意义(P＞0.05).6个月再住院率治疗组明显优与对照组,差异有统计学意义(P＜0.05).结论 临床治疗慢性心衰,在常规抗心衰药物治疗的基础上联合螺旋内脂优于联合缬沙坦.
作者 李洪林 刘凡 许家素
机构地区 重庆市大足县人民医院 重庆市第一人民医院
出处 《重庆医学》 CAS CSCD 2006年第16期1497-1498,共2页 Chongqing medicine
关键词 螺旋内脂 缬沙坦 慢性心力衰竭 血管紧张素Ⅱ受体拮抗剂 醛固酮拮抗剂
分类号 R541.6 [医药卫生—心血管疾病]
  • 相关文献

参考文献8

  • 1[1]Guyatt GH,Sullivan MJ,Thompson PJ,et al.The 6-minute walk:a new measure of exercise capacity in patients with chronic heart failure[J].Can Med Assoc,1985,32(8):919
  • 2[2]Packer M,Coats AJ,Fowler MB,et al.Effect of carvedilol on survival in severe chronic heart failure[J].N Engl J Med,2001,344:1651
  • 3郭志琴,刘坤申,彭应心,万国华,李延辉,卢雅敏.心力衰竭的醛固酮逃逸现象及螺内酯干预[J].中华心血管病杂志,2001,29(11):660-662. 被引量：29
  • 4柴晓利,龙先瑜.卡托普利和缬沙坦联合治疗充血性心力衰竭的临床观察[J].中国医师杂志,2005,7(9):1288-1289. 被引量：1
  • 5梁维基,冼洪光,陈镭.螺内酯对慢性心力衰竭患者神经体液及左心室功能的影响[J].中国医师杂志,2005,7(9):1289-1290. 被引量：8
  • 6赵林风 李永玲.安体舒通治疗慢性难治性心衰10例疗效观察[J].临床荟萃,2001,5(16):218-218.
  • 7[7]Yee KM,Pringle SD,Struthers AD.Circadian variation in the effects of aldosterone blockade on heart rate variabibity and QT dispersion in congestive heart failure[J].J Am Cardiol,2001,37:1800
  • 8[8]Pitt B,Zannad F,Remme WJ,et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized aldactone evaluation study investigators[J].N Engl J Med,1999,34:709

二级参考文献13

  • 1赵水平.心脏内科研修精要[M].长沙：湖南科学技术出版社,2000.77.
  • 2Cruden NL, Newby DE.Angiotensin antagonism in patients with heart failure: ACE inhibitor sangiotensin receptor antagonists or both?[J]. Am J Cardiovasc Drugs,2004,4(6):345-353.
  • 3Gring CN, Francis GS. A hard look at angiotensin receptor blockers in heart failure[J].J Am Coll Cardiol, 2004, 44(9):1841-1846.
  • 4Voors AA, van Veldhuisen DJ. Role of angiotensin receptor blockers in patients with left ventricular dysfunction: lessons from CHARM and VALIANT[J]. Int J Cardiol, 2004 , 97(3):345-348.
  • 5McMahon EG. Recent studies with eplerenone, a novel selective Aldosterone receptor Antagonist[J].Curr Opin pharmacol, 2001,1: 190-196.
  • 6Mckelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators[J]. Circulation, 1999,100:1056-1064.
  • 7Pitt B,Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with sever heart failure: Randomized Aldactone Evaluation Study Investigators[J]. N Engl J Med, 1999,341:709-717.
  • 8Bauersachs J, Heek M, Fraccarollo D, et al. Addition of spironolactone to angiotensin- converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: role of vascular superoxide anion formation and endothelial nitric oxide synthase expression[J]. J Am Coll Cardiol, 2002,39;351-358.
  • 9Beggah AT, Escoubet B, Puttini S, et al. Reversible cardiac fibrosis and heart failure induced by conditional expression of an antisense mRNA of the mineralocorticoid receptor in cardiomyocytes[J].Proc Natl Acad Sci USA,2002,99(10):7160-7165.
  • 10Bertram Pitt M.D.. “Escape” of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: Implications for therapy[J] 1995,Cardiovascular Drugs and Therapy(1):145～149

共引文献36

同被引文献19

  • 1李小鹰.慢性心力衰竭的治疗:从治疗指南到临床实践[J].中华内科杂志,2005,44(7):484-485. 被引量：37
  • 2刘华,李中原,庞学民.依那普利、螺内酯、倍他乐克联合应用治疗慢性心力衰竭疗效观察[J].临床荟萃,2006,21(14):1039-1040. 被引量：3
  • 3袁小媚,马康华.卡托普利和缬沙坦对大鼠心肌梗死后胶原网络重塑的干预研究[J].重庆医学,2006,35(15):1375-1377. 被引量：6
  • 4Braz J,Greqory K,Pathak A,et al. PKC-alpha regulates cardiac contractility and propensily toward heart failure[J]. Nat.Med,2004,10: 248-254.
  • 5Marx SO,Reiken S,Hisamatsu Y,et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel(ryanodinge receptor ) :defective regulation in failing hearts[J]. Cell,2000,101: 365-376.
  • 6Yano M,Kobayashi S,Kohno M,et al. FKBPI2.6-mediated stabilization of calcium-release channel (ryanodine receptor)as a novel therapeutic strategy against heart failure[J]. Cir,2003,107:477-484.
  • 7Coughtrie M W,Blair J N,Hume R,et al.Improved preparation of hepatic microsomes for in vitro diagnosis of inherited disorders of the glucose-6-phosphatase system[J]. Clin Chem,1991,37(5):739-742.
  • 8Masafumi Y,Yasuhiro l,Masunori M,et al. Altered intracellular Ca^2+ handling in heartfailure[J].Clin Invest,2005,115:556-564.
  • 9Mori T,Hayashi T,Sohmiya K,et al. Mechanisms of combined treatment with celiprolol and candesartan for ventricutar remodeling in experimental heart failure[J]. Cir,2005,69:596-602.
  • 10Bruckschlegel G,Holmer S R,Jandeleit K,et al. Effect of aldosterone receptor antagonist and angiotenisin Ⅱ type Ⅰ receptor blocker on cardiac transcriptional factors and mRNA expression in rats with myocardial infarction[J]. Circulation,2004,68:376-382.

引证文献2

二级引证文献10

重庆医学
2006年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部